{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:44Z","timestamp":1791655544863,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Supportive Oncology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.suponc.2010.09.003","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T06:54:50Z","timestamp":1297925690000},"page":"202-208","source":"Crossref","is-referenced-by-count":7,"title":["A Prospective Crossover Pilot Study to Evaluate the Use of a Topical Wound Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor Inhibitors"],"prefix":"10.1016","volume":"8","author":[{"given":"Siu-Fun","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Mummaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Arenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Alexson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Osann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suponc.2010.09.003_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.bi.48.070179.001205","article-title":"Epidermal growth factor","volume":"48","author":"Carpenter","year":"1979","journal-title":"Annu Rev Biochem"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2010.09.003_bib2","first-page":"S5","article-title":"Novel anticancer agents in clinical development","volume":"2","author":"Adjei","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.suponc.2010.09.003_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor\u2013related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.suponc.2010.09.003_bib4","first-page":"1339","article-title":"The new generation of targeted therapies for breast cancer","volume":"17","author":"Syed","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.suponc.2010.09.003_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3109\/07357909109018953","article-title":"The EGF receptor system as a target for antitumor therapy","volume":"9","author":"Ennis","year":"1991","journal-title":"Cancer Invest"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2010.09.003_bib6","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3816\/CLC.2004.s.010","article-title":"Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer","volume":"6","author":"Perez-Soler","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.suponc.2010.09.003_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.suponc.2010.09.003_bib11","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib12","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib13","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib15","first-page":"22","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","author":"Saltz","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor\u2013associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.suponc.2010.09.003_bib17","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor\u2013associated rash: future directions for management and investigation outcomes from the HER1\/EGFR Inhibitor Rash Management Forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.suponc.2010.09.003_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2010.09.003_bib21","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLC.2006.s.008","article-title":"Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer","volume":"8","author":"Perez-Soler","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3816\/CCC.2008.n.007","article-title":"Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic\/dermatologic cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin Colorectal Cancer"},{"issue":"11 suppl 5","key":"10.1016\/j.suponc.2010.09.003_bib23","first-page":"10","article-title":"Clinical research of EGFR inhibitors and related dermatologic toxicities","volume":"21","author":"Perez-Soler","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.suponc.2010.09.003_bib24","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor\u2013induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"issue":"suppl","key":"10.1016\/j.suponc.2010.09.003_bib26","first-page":"18S","article-title":"Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment for panitumumab (pmab)\u2013related ST in patients with metastatic colorectal cancer","volume":"17","author":"Mitchell","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11 suppl 5","key":"10.1016\/j.suponc.2010.09.003_bib27","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"11 suppl 5","key":"10.1016\/j.suponc.2010.09.003_bib28","first-page":"17","article-title":"Clinical management of EGFRI dermatologic toxicities: US perspective","volume":"21","author":"Lacouture","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.suponc.2010.09.003_bib29","series-title":"Drug Facts and Comparisons","year":"2009"},{"key":"10.1016\/j.suponc.2010.09.003_bib30","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.01341-06","article-title":"Tetracycline resistance in group A streptococci: emergence on a global scale and influence on multiple-drug resistance","volume":"51","author":"Ayer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.suponc.2010.09.003_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0966-842X(00)88930-1","article-title":"Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons","volume":"3","author":"Clewell","year":"1995","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.suponc.2010.09.003_bib32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1128\/AAC.42.8.1871","article-title":"Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants","volume":"42","author":"Rice","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.suponc.2010.09.003_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.01484-06","article-title":"Genetic elements carrying erm(B) in Streptococcus pyogenes and association with tet(M) tetracycline resistance gene","volume":"51","author":"Brenciani","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.suponc.2010.09.003_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jac\/dkm120","article-title":"New Tn916-related elements causing erm(B)-mediated erythromycin resistance in tetracycline-susceptible pneumococci","volume":"60","author":"Cochetti","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.suponc.2010.09.003_bib35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1902\/jop.2004.75.3.453","article-title":"Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug","volume":"75","author":"Lee","year":"2004","journal-title":"J Periodontol"},{"key":"10.1016\/j.suponc.2010.09.003_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/0929867013373570","article-title":"A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury","volume":"8","author":"Nieman","year":"2001","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.suponc.2010.09.003_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib39","first-page":"338","article-title":"Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer","volume":"10","author":"Li","year":"2009","journal-title":"JOP"},{"key":"10.1016\/j.suponc.2010.09.003_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3816\/CLC.2008.n.010","article-title":"Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity","volume":"9","author":"Grenader","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpainsymman.2005.06.001","article-title":"High doses of topically applied lidocaine in a cancer patient","volume":"30","author":"Wilhelm","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.suponc.2010.09.003_bib42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10133","article-title":"Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster","volume":"91","author":"Campbell","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.suponc.2010.09.003_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.suponc.2010.09.003_bib44","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1748-717X-3-5","article-title":"Severe skin reaction secondary to concomitant radiotherapy plus cetuximab","volume":"3","author":"Berger","year":"2008","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.lungcan.2008.09.009","article-title":"EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment","volume":"64","author":"Huang","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.suponc.2010.09.003_bib47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdm444","article-title":"Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment","volume":"19","author":"Tan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suponc.2010.09.003_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2005.12.004","article-title":"Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer","volume":"52","author":"Fujiwara","year":"2006","journal-title":"Lung Cancer"}],"container-title":["The Journal of Supportive Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679410000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679410000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T16:06:37Z","timestamp":1560009997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544679410000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1544679410000042"],"URL":"https:\/\/doi.org\/10.1016\/j.suponc.2010.09.003","relation":{},"ISSN":["1544-6794"],"issn-type":[{"value":"1544-6794","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}